Bionomics is a biotechnology company specializing in the development of innovative ion channel modulators aimed at treating serious central nervous system (CNS) disorders, particularly anxiety and stress-related conditions. The company leverages its expertise in ion channel biology and translational medicine to create small molecules that modulate ion channel function and influence neurotransmission. Their lead compound, BNC210, is a proprietary Negative Allosteric Modulator (NAM) of the α7 receptor, designed to provide anxiolytic and antidepressant effects without the sedative, habit-forming, or cognitive impairing side effects commonly associated with traditional treatments. BNC210 is currently undergoing late-stage clinical trials for Social Anxiety Disorder and is in the startup phase for Post-Traumatic Stress Disorder.

In addition to BNC210, Bionomics is advancing several other programs targeting various ion channels. Their next-generation α7 nicotinic acetylcholine receptor NAM program focuses on developing orally bioavailable small molecules for CNS disorders with significant unmet clinical needs. The Kv3.1/3.2 program aims to enhance cognitive function and address negative symptoms in conditions such as schizophrenia and Alzheimer’s Disease through the activation of specific potassium ion channels. Furthermore, the Pan Nav program targets voltage-gated sodium channels (Nav1.7, Nav1.8, and Nav1.9) to develop inhibitors that may provide relief for chronic pain syndromes. These initiatives highlight Bionomics' commitment to addressing critical gaps in the treatment landscape for CNS disorders and pain management.

Australia

Bionomics is a global, clinical stage biopharmaceutical company focused on leveraging its ion channel and chemistry platform to develop novel and first-in-class ion channel modulators to treat patients suffering from central nervous system disorders and cancer.

Bionomics

Company Details